Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > BROWSE ARTICLES > Author index
Search
Hyun Min Kim  (Kim HM) 8 Articles
Miscellaneous
Corrigendum: Correction of Acknowledgments. Metformin and Cervical Cancer Risk in Patients with Newly Diagnosed Type 2 Diabetes: A Population-Based Study in Korea
Hyun Min Kim, Min Jin Kang, Sun Ok Song
Endocrinol Metab. 2023;38(1):174.   Published online January 25, 2023
DOI: https://doi.org/10.3803/EnM.2023.101
Corrects: Endocrinol Metab 2022;37(6):929
  • 1,177 View
  • 102 Download
PDFPubReader   ePub   
Close layer
Diabetes, Obesity and Metabolism
Big Data Articles (National Health Insurance Service Database)
Metformin and Cervical Cancer Risk in Patients with Newly Diagnosed Type 2 Diabetes: A Population-Based Study in Korea
Hyun Min Kim, Min Jin Kang, Sun Ok Song
Endocrinol Metab. 2022;37(6):929-937.   Published online December 26, 2022
DOI: https://doi.org/10.3803/EnM.2022.1613
Correction in: Endocrinol Metab 2023;38(1):174
  • 2,609 View
  • 220 Download
  • 3 Web of Science
  • 3 Crossref
AbstractAbstract PDFPubReader   ePub   
Background
Cervical cancer is a prevalent malignancy that is a major health problem for women worldwide. The cancer-preventive properties of metformin are well-known, but insufficient data have been reported regarding its relationship to cervical cancer. Therefore, in a nationwide population-based study, we investigated the association between metformin use and cervical cancer incidence in patients with newly diagnosed type 2 diabetes.
Methods
This retrospective cohort study used the Korean National Health Insurance claims database. Individuals newly diagnosed with type 2 diabetes between January 2005 and December 2009 were included. The occurrence of cervical cancer was explored by matching for age, economic status, region of residence, and use of anti-diabetic medication.
Results
In total, 66,013 metformin users and 64,756 non-users were analyzed. Cervical cancer occurred in 219 metformin users (0.33%) and 274 metformin non-users (0.42%) (hazard ratio [HR], 0.783; 95% confidence interval [CI], 0.655 to 0.036; P=0.007). Moreover, cervical cancer risk was considerably reduced in those treated with a high dose (>1,200,000 mg) or for an extended period (≥2,000 days) compared to non-users (HR, 0.151; 95% CI, 0.093 to 0.243; P<0.001; and HR, 0.141; 95% CI, 0.077 to 0.258; P<0.001). The incidence was also significantly lower in metformin users among those over 50 years old (HR, 0.791; 95% CI, 0.650 to 0.961; P<0.001).
Conclusion
Metformin use in patients with newly diagnosed diabetes was associated with a lower risk of cervical cancer in Korea. Furthermore, a significant association was found between the use of metformin and cervical cancer in a dose- and duration-dependent manner and among those over 50 years old.

Citations

Citations to this article as recorded by  
  • Repurposing of Chronically Used Drugs in Cancer Therapy: A Chance to Grasp
    Mohamad Ali Hijazi, André Gessner, Nahed El-Najjar
    Cancers.2023; 15(12): 3199.     CrossRef
  • Network-based drug repurposing for HPV-associated cervical cancer
    Faheem Ahmed, Young Jin Yang, Anupama Samantasinghar, Young Woo Kim, Jeong Beom Ko, Kyung Hyun Choi
    Computational and Structural Biotechnology Journal.2023; 21: 5186.     CrossRef
  • The Use of Metformin and Postoperative Insulin Pump Were Predictive Factors for Outcomes of Diabetic Colorectal Cancer Patients after Surgery
    Xu-Rui Liu, Fei Liu, Zi-Wei Li, Quan Lv, Xin-Peng Shu, Lian-Shuo Li, Yue Tong, Wei Zhang, Dong Peng
    Nutrition and Cancer.2023; 75(10): 1926.     CrossRef
Close layer
Diabetes, Obesity and Metabolism
The Leg Fat to Total Fat Ratio Is Associated with Lower Risks of Non-Alcoholic Fatty Liver Disease and Less Severe Hepatic Fibrosis: Results from Nationwide Surveys (KNHANES 2008–2011)
Hyun Min Kim, Yong-ho Lee
Endocrinol Metab. 2021;36(6):1232-1242.   Published online November 23, 2021
DOI: https://doi.org/10.3803/EnM.2021.1087
  • 3,935 View
  • 131 Download
  • 3 Web of Science
  • 3 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
The prevalence of non-alcoholic fatty liver disease (NAFLD) has rapidly increased worldwide. The aim of this study was to investigate whether there is an independent relationship between regional fat distribution, especially leg fat mass, and the presence of NAFLD using nationally representative data in Korea.
Methods
This cross-sectional study analyzed data from 14,502 participants in the Korea National Health and Nutrition Examination Survey 2008 to 2011. Total fat mass, leg fat mass, and appendicular skeletal muscle mass were measured by dual-energy X-ray absorptiometry. Validated NAFLD prediction models and scoring systems for hepatic fibrosis were used.
Results
The leg fat to total fat (LF/TF) ratio showed a negative relationship with many factors, including body mass index, waist circumference, blood pressure, fasting blood glucose, and liver enzyme levels. When the LF/TF ratio and indices of hepatic steatosis were stratified by quartiles, the LF/TF ratio showed a negative correlation with the scoring systems that were used. The LF/TF ratio showed better accuracy in predicting NAFLD than total fat mass or leg fat mass alone. After adjusting for various traditional and lifestyle factors, a low LF/TF ratio remained a risk factor for NAFLD. Among NAFLD subjects, the LF/TF ratio showed a negative relationship with hepatic fibrosis.
Conclusion
A lower LF/TF ratio was markedly associated with a higher risk of hepatic steatosis and advanced hepatic fibrosis using various predictive models in a Korean population. Therefore, the LF/TF ratio could be a useful anthropometric parameter to predict NAFLD or advanced hepatic fibrosis.

Citations

Citations to this article as recorded by  
  • Waistline to thigh circumference ratio as a predictor of MAFLD: a health care worker study with 2-year follow-up
    Xiaoyan Hao, Honghai He, Liyuan Tao, Wei Zhao, Peng Wang
    BMC Gastroenterology.2024;[Epub]     CrossRef
  • A greater ratio of thigh subcutaneous fat to abdominal fat is associated with protection against non-alcoholic fatty liver disease
    Yebei Liang, Peizhu Chen, Siyu Chen, Dan Liu, Fusong Jiang, Zhijun Zhu, Keqing Dong, Li Wei, Xuhong Hou
    JHEP Reports.2023; 5(7): 100730.     CrossRef
  • Association between Alcohol Consumption and Metabolic Dysfunction-Associated Steatotic Liver Disease Based on Alcohol Flushing Response in Men: The Korea National Health and Nutrition Examination Survey 2019–2021
    Dae Eon Kang, Si Nae Oh
    Nutrients.2023; 15(18): 3901.     CrossRef
Close layer
Clinical Study
Trends in Hyperglycemic Crisis Hospitalizations and in- and out-of-Hospital Mortality in the Last Decade Based on Korean National Health Insurance Claims Data
Ji Hong You, Sun Ok Song, Se Hee Park, Kyoung Hye Park, Joo Young Nam, Dong Wook Kim, Hyun Min Kim, Dong-Jun Kim, Yong-ho Lee, Byung-Wan Lee
Endocrinol Metab. 2019;34(3):275-281.   Published online September 26, 2019
DOI: https://doi.org/10.3803/EnM.2019.34.3.275
  • 7,374 View
  • 98 Download
  • 8 Web of Science
  • 10 Crossref
AbstractAbstract PDFPubReader   ePub   
Background

Hyperglycemic crisis is a metabolic emergency associated with diabetes mellitus. However, accurate epidemiologic information on cases of hyperglycemic crisis in Korea remains scarce. We evaluated trends in hyperglycemic crisis hospitalizations and in- and out-of-hospital mortality in Korea. We also predicted future trends.

Methods

We extracted claims data with hyperglycemic crisis as the principal diagnosis from the National Health Insurance Service database in Korea from January 2004 to December 2013. We investigated the numbers of claims with hyperglycemic crisis and identified trends in hyperglycemic crisis based on those claims data. We predicted future trends by statistical estimation.

Results

The total annual number of claims of hyperglycemic crisis increased from 2,674 in 2004 to 5,540 in 2013. Statistical analysis revealed an increasing trend in hyperglycemic crisis hospitalizations (P for trend <0.01). In contrast, the hospitalization rate per 1,000 diabetes cases showed a decreasing trend (P for trend <0.01) during this period. The mortality rate per 1,000 diabetes cases also showed a decreasing trend (P for trend <0.0001). However, no distinct linear trend in the case-related fatality rate at <60 days over the last decade was observed. The predicted number of annual claims of hyperglycemic crisis will increase by 2030.

Conclusion

The number of hyperglycemic crisis hospitalizations in Korea increased in the last decade, although the hospitalization rate per 1,000 diabetes cases and mortality rate decreased. Also, the predicted number of annual claims will increase in the future. Thus, it is necessary to establish long-term healthcare policies to prevent hyperglycemic crisis.

Citations

Citations to this article as recorded by  
  • Enhancing outcome prediction by applying the 2019 WHO DM classification to adults with hyperglycemic crises: A single-center cohort in Thailand
    Chatchon Kaewkrasaesin, Weerapat Kositanurit, Phawinpon Chotwanvirat, Nitchakarn Laichuthai
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2024; 18(4): 103012.     CrossRef
  • Obesity and 30-day case fatality after hyperglycemic crisis hospitalizations in Korea: a national cohort study
    Hojun Yoon, Hyun Ho Choi, Giwoong Choi, Sun Ok Song, Kyoung Hwa Ha, Dae Jung Kim
    Cardiovascular Prevention and Pharmacotherapy.2023; 5(3): 74.     CrossRef
  • Interpreting global trends in type 2 diabetes complications and mortality
    Mohammed K. Ali, Jonathan Pearson-Stuttard, Elizabeth Selvin, Edward W. Gregg
    Diabetologia.2022; 65(1): 3.     CrossRef
  • Comparison of the clinical characteristics and outcomes of pediatric patients with and without diabetic ketoacidosis at the time of type 1 diabetes diagnosis
    Young-Jun Seo, Chang Dae Kum, Jung Gi Rho, Young Suk Shim, Hae Sang Lee, Jin Soon Hwang
    Annals of Pediatric Endocrinology & Metabolism.2022; 27(2): 126.     CrossRef
  • Clinical characteristics and outcomes of care in patients hospitalized with diabetic ketoacidosis
    Mohsen S. Eledrisi, Haifaa Alkabbani, Malk Aboawon, Aya Ali, Imad Alabdulrazzak, Maab Elhaj, Ashraf Ahmed, Hazim Alqahwachi, Joanne Daghfal, Salem A. Beshyah, Rayaz A. Malik
    Diabetes Research and Clinical Practice.2022; 192: 110041.     CrossRef
  • Hyperglycemic Crisis Characteristics and Outcome of Care in Adult Patients without and with a History of Diabetes in Tigrai, Ethiopia: Comparative Study
    Getachew Gebremedhin, Fikre Enqueselassie, Helen Yifter, Negussie Deyessa
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2021; Volume 14: 547.     CrossRef
  • Increased Incidence of Pediatric Diabetic Ketoacidosis After COVID-19: A Two-Center Retrospective Study in Korea
    Min Jeong Han, Jun Ho Heo
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2021; Volume 14: 783.     CrossRef
  • Acute Hyperglycemic Crises with Coronavirus Disease-19: Case Reports
    Na-young Kim, Eunyeong Ha, Jun Sung Moon, Yong-Hoon Lee, Eun Young Choi
    Diabetes & Metabolism Journal.2020; 44(2): 349.     CrossRef
  • Letter: Trends in Hyperglycemic Crisis Hospitalizations and in- and out-of-Hospital Mortality in the Last Decade Based on Korean National Health Insurance Claims Data (Endocrinol Metab 2019;34:275–81, Ji Hong You et al.)
    Jang Won Son
    Endocrinology and Metabolism.2019; 34(4): 422.     CrossRef
  • Response: Trends in Hyperglycemic Crisis Hospitalizations and in- and out-of-Hospital Mortality in the Last Decade Based on Korean National Health Insurance Claims Data (Endocrinol Metab 2019;34:275–81, Ji Hong You et al.)
    Ji Hong You, Sun Ok Song
    Endocrinology and Metabolism.2019; 34(4): 424.     CrossRef
Close layer
Obesity and Metabolism
Optimal Candidates for the Switch from Glimepiride to Sitagliptin to Reduce Hypoglycemia in Patients with Type 2 Diabetes Mellitus
Hyun Min Kim, Jung Soo Lim, Byung-Wan Lee, Eun-Seok Kang, Hyun Chul Lee, Bong-Soo Cha
Endocrinol Metab. 2015;30(1):84-91.   Published online March 27, 2015
DOI: https://doi.org/10.3803/EnM.2015.30.1.84
  • 5,961 View
  • 99 Download
  • 12 Web of Science
  • 11 Crossref
AbstractAbstract PDFPubReader   
Background

Sitagliptin is a novel antidiabetic agent with a low risk for hypoglycemia. We investigated the efficacy and safety of sitagliptin when patients switched from a sulfonylurea to sitagliptin and identified good candidates for the switch.

Methods

Sixty-one patients with type 2 diabetes switched from glimepiride with metformin to sitagliptin with metformin due to clinical hypoglycemia. Serum glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), and 2-hour postprandial plasma glucose (2h-PPG) before and 12 and 24 weeks after the drug switch were checked.

Results

HbA1c and FPG levels did not change 12 or 24 weeks after the switch; however, the 2h-PPG level decreased from 218.0±67.5 mg/dL at baseline to 197.1±69.9 mg/dL at 12 weeks and 192.3±67.4 mg/dL at 24 weeks after switching drugs (P=0.045, P=0.018, respectively). All but one patient no longer experienced hypoglycemia after discontinuing glimepiride. In a multivariate logistic regression analysis, a high homeostasis model assessment of insulin resistance and low baseline HbA1c level were independent predictors of an HbA1c ≤7% after switching to sitagliptin.

Conclusion

Glycemic control was not aggravated in patients 24 weeks after the drug switch, and symptomatic hypoglycemia decreased significantly. Patients with dominant insulin resistance may be good candidates for switching from a sulfonylurea to sitagliptin to reduce hypoglycemia.

Citations

Citations to this article as recorded by  
  • Application of Machine Learning Methods for the Development of Antidiabetic Drugs
    Juanjuan Zhao, Pengcheng Xu, Xiujuan Liu, Xiaobo Ji, Minjie Li, Dev Sooranna, Xiaosheng Qu, Wencong Lu, Bing Niu
    Current Pharmaceutical Design.2022; 28(4): 260.     CrossRef
  • Efficacy and safety of dorzagliatin for type 2 diabetes mellitus: A meta-analysis and trial sequential analysis
    Yunfeng Yu, Xingyu Yang, Keke Tong, Shuang Yin, Gang Hu, Fei Zhang, Pengfei Jiang, Manli Zhou, Weixiong Jian
    Frontiers in Cardiovascular Medicine.2022;[Epub]     CrossRef
  • Factors associated with switching from sulphonylureas to dipeptidyl peptidase 4 inhibitors among patients with type 2 diabetes in the United States
    Xi Tan, Lingfeng Yang, Kamlesh Khunti, Ruya Zhang, Ye Zhang, Swapnil Rajpathak, Miao Yu
    Diabetes, Obesity and Metabolism.2021; 23(10): 2251.     CrossRef
  • Increased risk of adverse cardiovascular events by strict glycemic control after percutaneous coronary intervention (HbA1c < 6.5% at 2 years) in type 2 diabetes mellitus combined with acute coronary syndrome: a 5-years follow-up study
    Tiangui Yang, Peng Fu, Jie Chen, Xi Fu, Changlu Xu, Xiaoxia Liu, Tiesheng Niu
    Current Medical Research and Opinion.2021; 37(9): 1517.     CrossRef
  • Clinical analysis of pre-existing diabetes mellitus and dipeptidyl peptidase-4 inhibitors in patients with remitting seronegative symmetrical synovitis and pitting edema syndrome
    Yoshiro Horai, Tomoki Origuchi, Nozomi Iwanaga, Junichi Tokumitsu, Toshiyuki Ikeoka, Genpei Kuriya, Yasumori Izumi, Atsushi Kawakami
    Modern Rheumatology.2020; 30(4): 703.     CrossRef
  • The efficacy and safety of dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a Bayesian network meta-analysis of 58 randomized controlled trials
    Juan Ling, Peng Cheng, Long Ge, Ding-hua Zhang, An-chen Shi, Jin-hui Tian, Ya-jing Chen, Xiu-xia Li, Jing-yun Zhang, Ke-hu Yang
    Acta Diabetologica.2019; 56(3): 249.     CrossRef
  • Satisfaction and efficacy of switching from daily dipeptidyl peptidase-4 inhibitors to weekly trelagliptin in patients with type 2 diabetes—Randomized controlled study—
    Mayuko Oita, Hideaki Miyoshi, Kota Ono, Akinobu Nakamura, Kyu Yong Cho, Hiroshi Nomoto, Kohei Yamamoto, Kazuno Omori, Naoki Manda, Yoshio Kurihara, Shin Aoki, Tatsuya Atsumi
    Endocrine Journal.2018; 65(2): 141.     CrossRef
  • Efficacy and safety of evogliptin versus sitagliptin as add on to metformin alone in a combined russian-korean population. Evo-combi trial
    Alina Y. Babenko, Anna A. Mosikian, Igor E. Makarenko, Victoriya V. Leusheva, Evgeny V. Shlyakhto
    Diabetes mellitus.2018; 21(4): 241.     CrossRef
  • Effectiveness prediction of Evogliptin treatment in type 2 diabetes mellitus in russian-korean population
    Anna A. Mosikian, Alina Y. Babenko, Yulia A. Sevastyanova, Roman V. Drai, Evgenij V. Shlyakhto
    Diabetes mellitus.2018; 21(5): 333.     CrossRef
  • Comprehensive analysis of the Co-structures of dipeptidyl peptidase IV and its inhibitor
    Hiroyuki Nojima, Kazuhiko Kanou, Genki Terashi, Mayuko Takeda-Shitaka, Gaku Inoue, Koichiro Atsuda, Chihiro Itoh, Chie Iguchi, Hajime Matsubara
    BMC Structural Biology.2016;[Epub]     CrossRef
  • A genetic variant in GLP1R is associated with response to DPP-4 inhibitors in patients with type 2 diabetes
    Eugene Han, Hye Sun Park, Obin Kwon, Eun Yeong Choe, Hye Jin Wang, Yong-ho Lee, Sang-Hak Lee, Chul Hoon Kim, Lee-Kyung Kim, Soo Heon Kwak, Kyong Soo Park, Chul Sik Kim, Eun Seok Kang
    Medicine.2016; 95(44): e5155.     CrossRef
Close layer
A Case of Pituitary Adenoma with Simultaneous Secretion of TSH and GH.
Eun Young Lee, Cheol Ryong Ku, Hyun Min Kim, Woo Kyoung Lee, Jung Soo Lim, Sena Hwang, Do Hwan Kim, Dong Yeob Shin, Eun Jig Lee
Endocrinol Metab. 2011;26(2):160-165.   Published online June 1, 2011
DOI: https://doi.org/10.3803/EnM.2011.26.2.160
  • 3,002 View
  • 30 Download
  • 2 Crossref
AbstractAbstract PDF
Thyrotropin (TSH)-secreting pituitary adenoma is a very rare disease. In one-quarter of patients suffering from this disease, the pituitary tumor secretes other anterior pituitary hormones. Herein, we report a case of pituitary adenoma with simultaneous secretion of TSH and growth hormone (GH). A 34-year-old female visitied local hospital complaining of sweating, intermittent palpitation, and weight loss of 8 kg within 1 year. The patient had undergone trans-sphenoidal surgery 3 years prior for resolution of a TSH and GH co-secreting pituitary adenoma. She had been administered somatostatin analogue prior to visiting our hospital. The patient's GH levels were suppressed to below 1 ng/mL on the 75 g oral glucose tolerance test, and her basal insulin-like growth factor-I (IGF-I) level was within normal range. Thyroid function tests demonstrated increased levels of both free thyroxine and TSH. Sella-MRI revealed pituitary adenoma at the floor of the pituitary fossa, approximately 2 cm in height. Therefore, she was diagnosed with residual TSH-secreting pituitary adenoma. The patient again underwent trans-sphenoidal surgery and entered complete remission, based on hormone levels and MRI findings.

Citations

Citations to this article as recorded by  
  • Endoscopic Transsphenoidal Surgery of Pituitary Adenomas: Preliminary Results of the Neurosurgery Service of Hospital Cristo Redentor
    Gerson Perondi, Afonso Mariante, Fernando Azambuja, Gabriel Frizon Greggianin, Wanderson William dos Santos Dias, Giulia Pinzetta
    Arquivos Brasileiros de Neurocirurgia: Brazilian Neurosurgery.2023; 42(02): e89.     CrossRef
  • A case of a co-secreting TSH and growth hormone pituitary adenoma presenting with a thyroid nodule
    Laura Hamilton Adams, Derick Adams
    Endocrinology, Diabetes & Metabolism Case Reports.2018;[Epub]     CrossRef
Close layer
Correlation between Pituitary Insufficiency and Magnetic Resonance Imaging Finding in Non-Functioning Pituitary Adenomas.
Hyun Min Kim, Cheol Ryong Ku, Eun Young Lee, Woo Kyung Lee, Jung Soo Lim, Sena Hwang, Mi Jung Lee, Seung Ku Lee, Sun Ho Kim, Eun Jig Lee
Endocrinol Metab. 2010;25(4):310-315.   Published online December 1, 2010
DOI: https://doi.org/10.3803/EnM.2010.25.4.310
  • 2,080 View
  • 28 Download
  • 1 Crossref
AbstractAbstract PDF
BACKGROUND
Non-functioning pituitary adenomas (NFPAs) are characterized by the absence of clinical and biochemical evidence of pituitary hormone hypersecretion, and these tumors constitute approximately one third of all the tumors of the anterior pituitary. Recently, hormonal deficiencies have gradually evolved to become the leading presenting signs and symptoms in patients with NFPAs. We investigated pituitary hormonal insufficiencies according to the magnetic resonance imaging (MRI) findings in patients with NFPA. METHODS: We evaluated the patients who were newly diagnosed with NFPA from 1997 through 2009. Among them, we analyzed 387 patients who were tested for their combined pituitary function and who underwent MRI. The severity of the hypopituitarism was determined by the number of deficient axes of the pituitary hormones. On the MRI study, the maximal diameter of the tumor, Hardy's classification, the thickness of the pituitary gland and the presence of stalk compression were evaluated. RESULTS: The mean age was 46.85 +/- 12.93 years (range: 15-86) and 186 patients (48.1%) were male. As assessed on MRI, the tumor diameter was 27.87 +/- 9.93 mm, the thickness of the normal pituitary gland was 1.42 +/- 2.07 mm and stalk compression was observed in 201 patients (51.9%). Hypopituitarism was observed in 333 patients (86.0%). Deficiency for each pituitary hormone was most severe in the patients with Hardy type IIIA. Hypopituitarism was severe in the older age patients (P = 0.001) and the patients with a bigger tumor size (P < 0.001) and the presence of stalk compression (P < 0.001). However, the patients who had a thicker pituitary gland showed less severe hypopituitarism (P < 0.001). Multivariate analysis showed that age, tumor diameter and the thickness of pituitary gland were important determinants for pituitary deficiency (P = 0.004, P < 0.001, P = 0.022, respectively). CONCLUSION: The results suggest that the hormonal deficiencies in patient with NFPA were correlated with the MRI findings, and especially the tumor diameter and preservation of the pituitary gland.

Citations

Citations to this article as recorded by  
  • Clinical Parameters to Distinguish Silent Corticotroph Adenomas from Other Nonfunctioning Pituitary Adenomas
    Daham Kim, Cheol Ryong Ku, Se Hee Park, Ju Hyung Moon, Eui Hyun Kim, Sun Ho Kim, Eun Jig Lee
    World Neurosurgery.2018; 115: e464.     CrossRef
Close layer
Secondary Pituitary Hyperplasia Induced by Hashimoto's Thyroiditis Related Hypothyroidism: A Case Report.
Kwang Joon Kim, Hyun min Kim, Obin Kwon, Eun Young Park, Yong ho Lee, Jae Won Hong, Jin Wi, Eun Jig Lee
J Korean Endocr Soc. 2010;25(1):72-77.   Published online March 1, 2010
DOI: https://doi.org/10.3803/jkes.2010.25.1.72
  • 1,976 View
  • 33 Download
  • 2 Crossref
AbstractAbstract PDF
Pituitary hyperplasia associated with untreated primary hypothyroidism in children is a rare condition. There are only a few reports on this condition in children, and especially when pituitary hyperplasia is accompanied with Hashimoto thyroiditis and growth arrest. Here, we describe an unusual association of pituitary hyperplasia with hypothyroidism and growth retardation, and this was all caused by Hashimoto thyroiditis. Hormonal testing showed a low thyroxine level and a high thyroid stimulating hormone level, elevated anti-thyroglobulin, low growth hormone levels and prepubertal levels of gonadotropins. A large intrasellar mass expanding beyond the sella turcica was detected on magnetic resonance imaging (MRI). Homogeneous contrast enhancement of mass highly suggested that it was a pituitary hyperplasia rather than a pituitary tumor. Therapy with L-thyroxine resulted in rapid improvement of the clinical signs, including renewed growth, normalization of the hormone levels and resolution of the pituitary hyperplasia on MRI within 90 days. In children, prolonged unrecognized primary hypothyroidism might be accompanied by growth deficiency and pubertal disharmony. Physicians must be aware of pituitary hyperplasia in these cases.

Citations

Citations to this article as recorded by  
  • Pituitary macroadenoma secondary to Hashimoto’s thyroiditis: inadvertent diagnosis in a pre-pubertal girl
    Deepanjan Bhattacharya, Rakesh Kumar, Jaivinder Yadav
    Tropical Doctor.2020; 50(3): 240.     CrossRef
  • Pituitary Hyperplasia Secondary to Hypothyroidism Caused by Hashimoto's Thyroiditis in a Female Adolescent
    Jeoung Suk Kim, Min Sun Kim, Sun Jun Kim, Gyung Ho Chung, Pyoung Han Hwang, Dae-Yeol Lee
    Journal of Korean Society of Pediatric Endocrinology.2011; 16(3): 185.     CrossRef
Close layer

Endocrinol Metab : Endocrinology and Metabolism